Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different health outcomes. The findings show benefits for brain and heart health, but ...
Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...
Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...